Augmentation of endothelial function by endothelin antagonism in human saphenous vein conduits

A. S. Dumont, F. Lovren, J. H. McNeill, G. R. Sutherland, Christopher Triggle, T. J. Anderson, S. Verma

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Object. Cerebral revascularization with saphenous vein (SV) conduits is used in the management of hard-to-treat lesions that require deliberate arterial occlusion and in selected patients with occlusive vascular disease. Endothelial dysfunction is thought to contribute to acute perioperative vasospasm and chronic graft atherosclerosis. In the present study the authors examined the contribution of the potent vasoconstrictor endothelin-1 (ET-1) to endothelial dysfunction in human SVs. Methods. The effects of an ETA/B receptor antagonist (bosentan), an ETA receptor antagonist (BQ-123), and an ETB receptor antagonist (BQ-788) on in vitro endothelium-dependent and -independent responses were studied in human SVs. Vascular segments were obtained in 34 patients who had undergone revascularization procedures, and isometric dose-response curves (DRCs) were constructed using the isolated tissue bath procedure as follows: 1) cumulative DRCs to norepinephrine; and 2) DRCs to acetylcholine (ACh) and sodium nitroprusside in the absence and presence of bosentan, BQ-123, or BQ-788. Maximal vasodilatory responses and sensitivity were compared between groups. In the presence of bosentan (Experiment 1) and BQ-123 or BQ-788 (Experiment 2), ACh responses were significantly augmented (percent maximum relaxation values: 7 ± 2 [control] compared with 17 ± 3 [bosentan], p < 0.002 [Experiment 1]; and 12 ± 2 [control] compared with 29 ± 2 [BQ-123] and 25 ± 2 [BQ-788], p < 0.003 and p < 0.002, respectively [Experiment 2]). The sensitivity of SVs to ACh was unaffected by treatment. These beneficial effects were specific for the endothelium. Conclusions. Blockade of ET receptors significantly improves endothelial function in SVs. Furthermore, these effects appear to be independently and maximally mediated by antagonism of either ETA or ETB receptors. Interventions aimed at improving endothelial function may serve to counter perioperative vasospasm and impede atherosclerosis in SVs used for revascularization procedures.

Original languageEnglish
Pages (from-to)281-286
Number of pages6
JournalJournal of Neurosurgery
Volume94
Issue number2
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Endothelins
Saphenous Vein
Acetylcholine
Endothelium
Atherosclerosis
Cerebral Revascularization
Nitroprusside
Vasoconstrictor Agents
Endothelin-1
Baths
Vascular Diseases
Blood Vessels
Norepinephrine
Transplants
cyclo(Trp-Asp-Pro-Val-Leu)
BQ 788
bosentan
Therapeutics

Keywords

  • Bosentan
  • Cerebral revascularization
  • Endothelin
  • Saphenous vein

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Dumont, A. S., Lovren, F., McNeill, J. H., Sutherland, G. R., Triggle, C., Anderson, T. J., & Verma, S. (2001). Augmentation of endothelial function by endothelin antagonism in human saphenous vein conduits. Journal of Neurosurgery, 94(2), 281-286.

Augmentation of endothelial function by endothelin antagonism in human saphenous vein conduits. / Dumont, A. S.; Lovren, F.; McNeill, J. H.; Sutherland, G. R.; Triggle, Christopher; Anderson, T. J.; Verma, S.

In: Journal of Neurosurgery, Vol. 94, No. 2, 2001, p. 281-286.

Research output: Contribution to journalArticle

Dumont, AS, Lovren, F, McNeill, JH, Sutherland, GR, Triggle, C, Anderson, TJ & Verma, S 2001, 'Augmentation of endothelial function by endothelin antagonism in human saphenous vein conduits', Journal of Neurosurgery, vol. 94, no. 2, pp. 281-286.
Dumont AS, Lovren F, McNeill JH, Sutherland GR, Triggle C, Anderson TJ et al. Augmentation of endothelial function by endothelin antagonism in human saphenous vein conduits. Journal of Neurosurgery. 2001;94(2):281-286.
Dumont, A. S. ; Lovren, F. ; McNeill, J. H. ; Sutherland, G. R. ; Triggle, Christopher ; Anderson, T. J. ; Verma, S. / Augmentation of endothelial function by endothelin antagonism in human saphenous vein conduits. In: Journal of Neurosurgery. 2001 ; Vol. 94, No. 2. pp. 281-286.
@article{fb943e24f7594e8d8ec0d54361d4daad,
title = "Augmentation of endothelial function by endothelin antagonism in human saphenous vein conduits",
abstract = "Object. Cerebral revascularization with saphenous vein (SV) conduits is used in the management of hard-to-treat lesions that require deliberate arterial occlusion and in selected patients with occlusive vascular disease. Endothelial dysfunction is thought to contribute to acute perioperative vasospasm and chronic graft atherosclerosis. In the present study the authors examined the contribution of the potent vasoconstrictor endothelin-1 (ET-1) to endothelial dysfunction in human SVs. Methods. The effects of an ETA/B receptor antagonist (bosentan), an ETA receptor antagonist (BQ-123), and an ETB receptor antagonist (BQ-788) on in vitro endothelium-dependent and -independent responses were studied in human SVs. Vascular segments were obtained in 34 patients who had undergone revascularization procedures, and isometric dose-response curves (DRCs) were constructed using the isolated tissue bath procedure as follows: 1) cumulative DRCs to norepinephrine; and 2) DRCs to acetylcholine (ACh) and sodium nitroprusside in the absence and presence of bosentan, BQ-123, or BQ-788. Maximal vasodilatory responses and sensitivity were compared between groups. In the presence of bosentan (Experiment 1) and BQ-123 or BQ-788 (Experiment 2), ACh responses were significantly augmented (percent maximum relaxation values: 7 ± 2 [control] compared with 17 ± 3 [bosentan], p < 0.002 [Experiment 1]; and 12 ± 2 [control] compared with 29 ± 2 [BQ-123] and 25 ± 2 [BQ-788], p < 0.003 and p < 0.002, respectively [Experiment 2]). The sensitivity of SVs to ACh was unaffected by treatment. These beneficial effects were specific for the endothelium. Conclusions. Blockade of ET receptors significantly improves endothelial function in SVs. Furthermore, these effects appear to be independently and maximally mediated by antagonism of either ETA or ETB receptors. Interventions aimed at improving endothelial function may serve to counter perioperative vasospasm and impede atherosclerosis in SVs used for revascularization procedures.",
keywords = "Bosentan, Cerebral revascularization, Endothelin, Saphenous vein",
author = "Dumont, {A. S.} and F. Lovren and McNeill, {J. H.} and Sutherland, {G. R.} and Christopher Triggle and Anderson, {T. J.} and S. Verma",
year = "2001",
language = "English",
volume = "94",
pages = "281--286",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "2",

}

TY - JOUR

T1 - Augmentation of endothelial function by endothelin antagonism in human saphenous vein conduits

AU - Dumont, A. S.

AU - Lovren, F.

AU - McNeill, J. H.

AU - Sutherland, G. R.

AU - Triggle, Christopher

AU - Anderson, T. J.

AU - Verma, S.

PY - 2001

Y1 - 2001

N2 - Object. Cerebral revascularization with saphenous vein (SV) conduits is used in the management of hard-to-treat lesions that require deliberate arterial occlusion and in selected patients with occlusive vascular disease. Endothelial dysfunction is thought to contribute to acute perioperative vasospasm and chronic graft atherosclerosis. In the present study the authors examined the contribution of the potent vasoconstrictor endothelin-1 (ET-1) to endothelial dysfunction in human SVs. Methods. The effects of an ETA/B receptor antagonist (bosentan), an ETA receptor antagonist (BQ-123), and an ETB receptor antagonist (BQ-788) on in vitro endothelium-dependent and -independent responses were studied in human SVs. Vascular segments were obtained in 34 patients who had undergone revascularization procedures, and isometric dose-response curves (DRCs) were constructed using the isolated tissue bath procedure as follows: 1) cumulative DRCs to norepinephrine; and 2) DRCs to acetylcholine (ACh) and sodium nitroprusside in the absence and presence of bosentan, BQ-123, or BQ-788. Maximal vasodilatory responses and sensitivity were compared between groups. In the presence of bosentan (Experiment 1) and BQ-123 or BQ-788 (Experiment 2), ACh responses were significantly augmented (percent maximum relaxation values: 7 ± 2 [control] compared with 17 ± 3 [bosentan], p < 0.002 [Experiment 1]; and 12 ± 2 [control] compared with 29 ± 2 [BQ-123] and 25 ± 2 [BQ-788], p < 0.003 and p < 0.002, respectively [Experiment 2]). The sensitivity of SVs to ACh was unaffected by treatment. These beneficial effects were specific for the endothelium. Conclusions. Blockade of ET receptors significantly improves endothelial function in SVs. Furthermore, these effects appear to be independently and maximally mediated by antagonism of either ETA or ETB receptors. Interventions aimed at improving endothelial function may serve to counter perioperative vasospasm and impede atherosclerosis in SVs used for revascularization procedures.

AB - Object. Cerebral revascularization with saphenous vein (SV) conduits is used in the management of hard-to-treat lesions that require deliberate arterial occlusion and in selected patients with occlusive vascular disease. Endothelial dysfunction is thought to contribute to acute perioperative vasospasm and chronic graft atherosclerosis. In the present study the authors examined the contribution of the potent vasoconstrictor endothelin-1 (ET-1) to endothelial dysfunction in human SVs. Methods. The effects of an ETA/B receptor antagonist (bosentan), an ETA receptor antagonist (BQ-123), and an ETB receptor antagonist (BQ-788) on in vitro endothelium-dependent and -independent responses were studied in human SVs. Vascular segments were obtained in 34 patients who had undergone revascularization procedures, and isometric dose-response curves (DRCs) were constructed using the isolated tissue bath procedure as follows: 1) cumulative DRCs to norepinephrine; and 2) DRCs to acetylcholine (ACh) and sodium nitroprusside in the absence and presence of bosentan, BQ-123, or BQ-788. Maximal vasodilatory responses and sensitivity were compared between groups. In the presence of bosentan (Experiment 1) and BQ-123 or BQ-788 (Experiment 2), ACh responses were significantly augmented (percent maximum relaxation values: 7 ± 2 [control] compared with 17 ± 3 [bosentan], p < 0.002 [Experiment 1]; and 12 ± 2 [control] compared with 29 ± 2 [BQ-123] and 25 ± 2 [BQ-788], p < 0.003 and p < 0.002, respectively [Experiment 2]). The sensitivity of SVs to ACh was unaffected by treatment. These beneficial effects were specific for the endothelium. Conclusions. Blockade of ET receptors significantly improves endothelial function in SVs. Furthermore, these effects appear to be independently and maximally mediated by antagonism of either ETA or ETB receptors. Interventions aimed at improving endothelial function may serve to counter perioperative vasospasm and impede atherosclerosis in SVs used for revascularization procedures.

KW - Bosentan

KW - Cerebral revascularization

KW - Endothelin

KW - Saphenous vein

UR - http://www.scopus.com/inward/record.url?scp=0034866937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034866937&partnerID=8YFLogxK

M3 - Article

VL - 94

SP - 281

EP - 286

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 2

ER -